Clinical assessment of vasodilating carvedilol effects in patients with arterial hypertension and overweight/obesity: CAMELIA Study results
Aim. To compare the effects of two beta-adrenoblockers (BAB) – a generic carvedilol and metoprolol tartrate – on lipid profile, carbohydrate and purine metabolism parameters in patients with arterial hypertension (AH) and overweight or obesity (OW/O). Material and methods. The study included 320 pat...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2158 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim. To compare the effects of two beta-adrenoblockers (BAB) – a generic carvedilol and metoprolol tartrate – on lipid profile, carbohydrate and purine metabolism parameters in patients with arterial hypertension (AH) and overweight or obesity (OW/O). Material and methods. The study included 320 patients, receiving carvedilol (n=160) or metoprolol tartrate (n=160) for 24 weeks. The effectiveness of antihypertensive therapy (AHT) was assessed by blood pressure (BP) dynamics at each visit and at the end of the study, comparing to baseline BP levels. Safety parameters included adverse event (AE) profile and biochemical parameter dynamics (lipid profile, glucose, creatinine (Cr), uric acid (UA), potassium (К+) and sodium (Na+)). Results. As early as at the first visits, a significant reduction in baseline levels of systolic and diastolic BP (SBP, DBP) was observed (р<0,0001). Both carvedilol and metoprolol therapy resulted in a significant reduction of heart rate (HR) and body mass index, BMI (by 0,39±0,07 kg/m2 (р<0,0001) at the end of the study). Carvedilol therapy was associated with improved lipid profile and glycemia parameters, while metoprolol was metabolically neutral. One of the new, positive findings was the absence of adverse effects of carvedilol-based AHT on purine metabolism. Conclusion. In patients with Stage 1-2 AH and OW/O, a good antihypertensive effect was observed for both medications studied. The latter, due to its additional vasodilating effect, demonstrated beneficial effects on AH-associated metabolic parameters. Therefore, carvedilol should be a BAB of choice in patients with AH and metabolic risk factors. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |